HUTCHMED (LON:HCM) Trading 16.4% Higher – Still a Buy?

Posted by Geri Gentry on Sep 3rd, 2026

HUTCHMED (China) Limited (LON:HCM – Get Free Report) shot up 16.4% during mid-day trading on Thursday . The stock traded as high as GBX 212 and last traded at GBX 209. Approximately 497,827 shares changed hands during mid-day trading, an increase of 1,204% from the average session volume of 38,169 shares. The stock had previously closed at GBX 179.50.

HUTCHMED Stock Up 16.4%

The company has a 50-day simple moving average of GBX 175.49 and a 200-day simple moving average of GBX 189.79. The firm has a market cap of £1.82 billion, a PE ratio of 104.50 and a beta of 0.43. The company has a debt-to-equity ratio of 7.91, a current ratio of 4.96 and a quick ratio of 2.97.

About HUTCHMED

(Get Free Report)

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).

HUTCHMED (LON:HCM) Trading 16.4% Higher – Still a Buy?

HUTCHMED Stock Up 16.4%

About HUTCHMED

Further Reading

You might be interested in: